Premium
Influence of preoperative anti‐cancer therapy on resectability and perioperative outcomes in patients with pancreatic cancer: Project study by the J apanese S ociety of H epato‐ B iliary‐ P ancreatic S urgery
Author(s) -
Motoi Fuyuhiko,
Unno Michiaki,
Takahashi Hidenori,
Okada Takaho,
Wada Keita,
Sho Masayuki,
Nagano Hiroaki,
Matsumoto Ippei,
Satoi Sohei,
Murakami Yoshiaki,
Kishiwada Masashi,
Honda Goro,
Kinoshita Hisafumi,
Baba Hideo,
Hishinuma Shoichi,
Kitago Minoru,
Tajima Hidehiro,
Shinchi Hiroyuki,
Takamori Hiroshi,
Kosuge Tomoo,
Yamaue Hiroki,
Takada Tadahiro
Publication year - 2014
Publication title -
journal of hepato‐biliary‐pancreatic sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.63
H-Index - 60
eISSN - 1868-6982
pISSN - 1868-6974
DOI - 10.1002/jhbp.15
Subject(s) - perioperative , pancreatic cancer , medicine , cancer , general surgery , surgery
Background Little is known about the effects of neoadjuvant therapy on outcomes in patients with pancreatic cancer. This study evaluated the effects of neoadjuvant therapy on resectability and perioperative outcomes. Methods A total of 992 patients were enrolled, with 971 deemed eligible. Of these, 582 had resectable tumors and 389 had borderline resectable tumors, and 388 patients received neoadjuvant therapy. Demographic characteristics and peri‐ and postoperative parameters were assessed by a questionnaire survey. Results The R 0 rate was significantly higher in patients with resectable tumors who received neoadjuvant therapy than in those who underwent surgery first, but no significant difference was noted in patients with borderline resectable tumors. Operation time was significantly longer and blood loss was significantly greater in patients who received neoadjuvant therapy than in those who underwent surgery first, but there were no significant differences in specific complications and mortality rates. The node positivity rate was significantly lower in the neoadjuvant than in the surgery‐first group, indicating that the former had significantly lower stage tumors. Conclusions Neoadjuvant therapy may not increase the mortality and morbidity rate and may be able to increase the chance for curative resection against resectable tumor.